|
Lacrimal gland dysfunction is a major cause of dry eye disease
|
|
|
|
|
|
The era of antiaging ophthalmology comes of age: antiaging approach for dry eye treatment.
Tsubota K; Kawashima M; Inaba T; Dogru M; Ogawa Y; Nakamura S; Shinmura K; Higuchi A; Kawakita T.
Ophthalmic Research. 44(3):146-54, 2010.
|
|
|
|
|
|
Aging and dry eye disease.
Ding J; Sullivan DA.
Experimental Gerontology. 47:483, 2012.
|
|
|
|
|
|
The antiaging approach for the treatment of dry eye.
Tsubota K et al;
Cornea. 31: Suppl 1:S3, 2012.
Currently, there is no therapy available to recover lacrimal function to its normal status.
|
|
|
|
|
|
Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease.
Chhadva P; Goldhardt R; Galor A.
Ophthalmology. 124 (11S):S20-S26, 2017.
|
|
|
|
|
|
Advantage of AH-201-DE :
|
|
|
1.
|
Dry eye is an aging process of lacrimal gland of eye which is well recognized recently.
|
|
2.
|
AH-201-DE is the first small molecule through antiaging approach for dry eye drug discovery.
|
|
3.
|
AH-201-DE is an endogenous EPO inducer for activating mitochondria biogenesis and hemoglobin production in lacrimal gland.
|
|
4.
|
So far, no effective therapy for dry eye, AH-201-DE can expand the global market for dry eye.
|
|
|
|
|
Global market for dry eye
|
|
|
|
|
|
Transparency Market Research(2018,Jan)
estimates that the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Escalating at this pace, the market, which had a valuation of US$ 5 billion in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.
|
|
|
|
|
|
Ophthalmic Res 44:146, 2010
The Era of Antiaging Ophthalmology Comes of Age: Antiaging Approach for Dry Eye Treatment.
|
|
|
|
|
|
MedEdicus Proceeding from a CME symposium during AAO 2015
Addressing Unmet Needs in Dry Eye Disease.
|
|
|
|
|
|
THE Ocular Surface 14:264, 2016
Targeting the Unmet Need for Dry Eye Treatment
|
|
|
|
|